دورية أكاديمية
Is the Effect of Tumor Localization on Prognosis Compatible with Real-life Data in Metastatic Colon Cancer? Single-Center Experience: A Retrospective Analysis
| العنوان: | Is the Effect of Tumor Localization on Prognosis Compatible with Real-life Data in Metastatic Colon Cancer? Single-Center Experience: A Retrospective Analysis |
|---|---|
| المؤلفون: | Bulut, G., Oytun, M.G., Gökmen, E. |
| بيانات النشر: | Springer |
| سنة النشر: | 2022 |
| المجموعة: | Ege University Institutional Repository |
| مصطلحات موضوعية: | Metastatic colorectal cancer, Left vs right, Overall survival, Progression-free survival, Real-life data, Tumor localization, Tumor sidedness, vasculotropin antibody, adult, Article, cancer localization, cancer prognosis, cancer staging, colloid carcinoma, female, gene mutation, human, major clinical study, male, metastasis resection, metastatic colon cancer, oncogene K ras, progression free survival, retrospective study, treatment response, colon tumor, colorectal tumor, pathology, prognosis, Adenocarcinoma |
| الوصف: | Aim: In recent years, the prognostic and predictive value of primary tumor localization in colon cancer has become increasingly important. This study aimed to retrospectively analyze the effect of colon cancer tumor localization on progression-free survival, overall survival, and response to treatments and present real-life data. Method: Retrospective evaluation was made of 465 patients who were diagnosed with metastatic colorectal carcinoma between 2010 and 2015 in our clinic. The effect of primary tumor localization on progression-free survival, overall survival, and response to therapy was investigated. Results: The right colon cancer (RCC) was determined in 66 patients, 14.2% of the whole group, and left colorectal cancer (LCRC) in 399 patients which is 85.8% of patients. Mucinous adenocarcinoma was 16.7% in RCC; however, only 6.4% of LCRC had a mucinous tumor (p 0.05). Nodal involvement in any stage (N1 and N2) was 46.9% in right colon cancer whereas in LCRC, it was 41.2% (p 0.05). Primary tumor surgery (74.2% vs. 70.2%) and metastasectomy (33.3% vs. 19.4%) were also more common in RCC(p 0.05). k-ras mutation status was similar in both groups (28.8% in RCC vs 26.8% in LCRC, p > 0.05). Median progression-free survival was 12.6 months in RCC, and 15.5 in LCRC (p > 0.05). Median overall survival was 28.4 months in RCC and 33.5 months in LCRC (p > 0.05). In k-ras wild-type patients, the median overall survival was 32.3 months (95% CI 25.2–39.5) in the anti-VEGF antibody treatment group and 55.1 months (95% CI 36.5–73.7) in the anti-EGFR antibody treatment group (p 0.05). Conclusion: Although tumors located in the right colon have been considered to be worse in terms of progression-free and overall survival in clinical trials, the results of this study showed that in daily practice, there was no difference between left and right colon localized tumors in progression-free and overall survival. Further, in k-ras wild-type colon cancers, tumor localization predicts the treatment response. This study is ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1941-6628 |
| العلاقة: | Journal of Gastrointestinal Cancer; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://hdl.handle.net/11454/90094Test; https://doi.org/10.1007/s12029-021-00615-zTest; 53; 15 |
| DOI: | 10.1007/s12029-021-00615-z |
| الإتاحة: | https://doi.org/10.1007/s12029-021-00615-zTest https://hdl.handle.net/11454/90094Test |
| حقوق: | none |
| رقم الانضمام: | edsbas.3C16ACB8 |
| قاعدة البيانات: | BASE |
| تدمد: | 19416628 |
|---|---|
| DOI: | 10.1007/s12029-021-00615-z |